Dr. Martina Schüßler-Lenz
Dr. Martina Schüssler-Lenz is the Chair of the Committee for Advanced Therapies (CAT) of the European Medicines Agency's (EMA). The CAT is the committee responsible for evaluating the quality, safety and efficacy of marketing authorisations of cell and gene therapies (Advanced Therapy Medicinal Products, ATMPs).
She is working as M.D. at the Paul-Ehrlich Institute in the Section Advanced Therapies and Tissue Preparations.
Overall, Martina has 30 years of professional experience. She received her medical degree in Germany at Mainz University. She completed an Internal Medicine residency, is board certified in internal medicine and worked many years in Hematology/Medical Oncology. Based on a grant from the German Research Council DFG she moved on to New York for a postdoctoral fellowship in tumor biology and immunology at the Memorial Sloan Kettering Cancer Center, followed by a fellowship at the Instituto Municipal de investigacion Medica in Barcelona, Spain.
During her more than 10 years in the pharmaceutical industry she was responsible for several international clinical drug development projects of hematology and oncology products.
In 2005 she joined the Paul-Ehrlich-Institut, the German Federal Agency for Vaccines and Biomedicines, where she holds a position as Deputy Head in the Section Advanced Therapy Medicinal Products and is responsible for advising companies on drug development issues, reviewing clinical trials and marketing authorisations.
She has been a member of the EMA Committee for Advanced Therapies for many years and was elected as its chairperson in February 2017.
Her scientific and regulatory work has resulted in several (co-)authorships in scientific journals, as for example recently the “Clinical development of CAR-T cells – challenges and opportunities in translating innovative treatment concepts” in EMBO Molecular Medicine (online 1.8.2017 DOI 10.15252/emmm.201607485).